Press Releases Latest Jan 09, 2025 Theratechnologies Provides Update on EGRIFTA SV® Supply Press Releases Year None2025202420232022202120202019201820172016201520142013 Feb 16, 2023 Theratechnologies Announces Path to Resume TH1902 Clinical Development Feb 14, 2023 Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update Jan 04, 2023 Open Letter to Shareholders from CEO Paul Levesque Dec 01, 2022 Theratechnologies Announces Update from Ongoing TH1902 Study Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update Sep 19, 2022 Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference First page « Previous page ‹ … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page › Last page » Displaying 81 - 90 of 380
Feb 14, 2023 Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
Oct 03, 2022 Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
Sep 26, 2022 Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update